New Phase 3 trial: Phase 3, Multi-Center, Randomized, Double-Masked, Placebo-Controlled Study Assessing the Safety and Efficacy of Urcosimod Ophthalmic Solution in Participants With Neuropathic Corneal Pain (NCP). — Okyo Pharma Ltd
Why now
Thesis: Marginal pipeline event for a small sponsor
Catalyst to watch: Enrollment completion and topline data
Main risk: Small trial may not replicate prior efficacy
Why it matters
Small 111-patient Phase 3 in neuropathic corneal pain is a niche indication; outcome matters only to the sponsor's pipeline value.
Details
Sponsor: Okyo Pharma Ltd; Status: Not Yet Recruiting; Conditions: Neuropathic Corneal Pain; Interventions: Urcosimod ophthalmic solution is a preservative-free topical ophthalmic product; supplied in unit dose ampoules; administered QID for 12-weeks.; Enrollment: 111 (estimated); First posted: 2026-09-24; NCT: NCT07838506
Related assets & topics
HealthcareSources
- clinicaltrials · 2026-09-24 12:00 UTC